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ABBREVIATIONS 
APCs: antigen presenting cells 
APLs: altered peptide ligands 
DCs: dendritic cells 
EDTA: ethylen-diamine-tetraacetic acid 
ELISA: enzyme-linked immunosorbent assay 
FACS: flow cytometric cell analysis 
GILs: graft-infiltrating lymphocytes 
IFN: interferon 
IL: interleukin 
LEW: Lewis rat 
mAbs: monoclonal antibodies 
MHC: major histocompatibility complex 
PBS: phosphate buffered saline 
RT-PCR: reverse transcriptase-polymerase chain reaction 
TCR: T cell receptor 
WF: Wistar-Furth rat 
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1. INTRODUCTION 
Transplantation of vascularized organs is now the therapy of choice for end-stage 
organ failure. The major improvements in the field of surgical techniques, MHC 
matching and immunosuppressive drugs, are able to prolong the one-year survival of 
most solid organ grafts to over 90%. Since the transplant recipients require life-long 
immunosuppression with severe side-effects, in order to avoid tissue damage and 
disruption of their function, the major aim of transplantation immunology remains the 
downregulation of the allograft-induced immune response. The development of 
antigen-specific strategies should greatly facilitate the allograft-restricted suppression 
without the general compromise of the recipient’s defense system (Gorantla et al. 
2000). 
1.1 Alloimmune response: immunologic basis for allograft rejection 
After transplantation of MHC-incompatible tissues, the immune system is activated, 
leading finally to graft rejection. This is the major obstacle to successful 
transplantation. The principal targets of the immune response to an allogeneic tissue 
are the donor MHC molecules present on the grafted cells (Rogers et al. 2001). The 
term “allorecognition” describes the T cell recognition of genetically encoded MHC 
polymorphism between members of the same species.  
Lechler and Batchelor were the first to suggest that allorecognition occurs in two 
possible ways, through the direct or indirect pathway, respectively (Lechler et al. 
1982) (Figure 1). After allotransplantation, recipient T cells (CD4+ and/or CD8+) 
recognize intact donor MHC molecules displayed on the surface of donor grafted 
cells, so called “passenger leukocytes” (direct allorecognition), which are believed to 
be specialized APCs that provide all of the necessary stimulatory signals required for 
the activation of T cells. Direct allorecognition represents a special mechanism that 
occurs only after transplantation and can be explained by the cross-reactivity of T 
cells. The frequency of peripheral T cells that are able to recognize alloantigens is 1-
10% of the peripheral T cell population (Suchin et al. 2001). A few days after 
transplantation, donor MHC molecules are shed from the graft, taken up and 
processed into small fragments by self-APCs, followed by presentation in the groove 
of self-MHC class II molecules on the surface of self-APCs to CD4+ T cells (indirect 
   2 
CD8+
CD8+
Allograft destruction (rejection)
CD4+
Self-MHC class II
Passenger 
leukocytes
CD8+
Donor 
APC
Allo-MHC 
class I
Self APC
Donor
APC
CD4+
Allo-MHC 
class II
Self T 
cells
Macrophages
NK cells B cells
Cell mediated 
cytotoxicity Natural killing DTH inflammation
Antibody dependent 
cytotoxicity
Allo-MHC processing 
and presentation
Allo-MHC peptidePeptide
Cytokines
(A) Direct pathway  (B) Indirect pathway 
FIGURE 1. Two pathways are involved in the recognition of alloantigen by recipient T cells: the
direct (A) and the indirect pathway (B). 
allorecognition) (Auchincloss et al. 1993). The indirect pathway represents the 
physiological reaction against foreign antigens and depends on the continuous 
supply of alloantigens from the graft. It has been recently shown that CD4+ T cells 
play the central role in the allograft rejection through the indirect pathway 
(Auchincloss et al. 1996). Activated CD4+ T cells provide further help for the other 
effector cells to orchestrate the cellular and molecular mechanisms that finally lead to 
rejection.  
1.2 Current and new strategies to suppress the alloimmune response 
Transplantation between genetically different individuals evokes a quick and 
destructive alloimmune response that, in the absence of immunosuppression, leads 
to graft destruction. Since T cells are the central players in the alloimmune response, 
most of the current immunosuppressive drugs target the T cell activation and 
cytokine production, the clonal expansion, or both (Denton et al. 1999). 
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The immunosuppressive drugs developed in the past two decades have decreased 
the rate of acute graft rejection and improved the 1-year graft survival, but almost all 
the transplanted patients still require life-long immunosuppression. Moreover, these 
agents lack specificity and are associated with severe problems: (1) reduced 
immunity to infections and (2) malignant diseases, and (3) other drug-related adverse 
effects such as nephrotoxicity, hypertension, diabetes and hyperlipidaemia. 
The newly developed strategies block the interactions between T cells and APCs, 
inducing the inactivation rather than elimination of alloreactive T cells. The 
experimental protocols include monoclonal antibodies against CD4, CD154, LFA1, 
ICAM1, LFA3, CD2, CD45, and CTLA4-Ig (Yu et al. 2001). However, the use of such 
antibodies in some primate and human experiments has been associated with 
excessive side effects, thus proving to be insufficient and ineffective (Waldmann 
2001). 
As a consequence of the systemic immunosuppressive effects of the currently used 
protocols, the objective of transplantation is to develop antigen-specific strategies 
with minimal secondary effects. Thus, by suppressing only the anti-donor immune 
response it is possible to achieve immunological unresponsiveness to the graft, in the 
presence of a fully competent immune system.  
1.3 MHC peptides as modulators of the alloimmune response 
Since the donor MHC peptides represent the principal antigens in the initiation and 
maintenance of the alloimmune response, it is not surprising that most experimental 
studies are focused on the modulation of the alloimmune response using MHC 
allopeptides. It has been shown that some allopeptides have potential 
immunomodulatory capacities when administered intrathymically (Sayegh et al. 
1994), orally (Zavazava et al. 2000), or as peptide-pulsed recipient DCs (Ali et al. 
2001). Since these studies have been performed in animal models and the 
responsible mechanisms need to be further investigated and elucidated, their clinical 
applicability remains questionable.  
A more favorable approach is to alter the alloreactive T cell response by subtle 
changes in the sequence of the alloantigens. It has been demonstrated that there is 
only one optimal peptide ligand for each MHC-TCR complex; this ligand has both 
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MHC and TCR contact residues and fits well in the binding grooves (Figure 2). 
Peptide ligands with amino acid substitution in the MHC anchor positions are referred 
to as MHC anchor-modified ligands. In addition, peptides with modifications on the 
TCR contact sites, generally termed altered peptide ligands (APLs), are able to alter 
the TCR signaling (Bielekova et al. 2001). However, the definition of APLs has 
become enlarged and includes all the peptide analogues, which contain one or more 
substitutions at any residue (Anderton 2001). Table 1 shows the classification of 
APLs based on their outcome on the antigen-specific T cell response as compared to 
the natural peptide ligand.  
TABLE 1. Classification of altered peptide ligands according to their effects on the wild-type
(wt) antigen-specific T cells (after Anderton 2001).  
Up-regulation of the immune response Down-regulation of the immune response 
Agonist Induces response at 
equivalent doses to wild-
type (wt) antigen 
Partial agonist Qualitatively different activation: 
cytokine production or target 
lysis in absence of proliferation 
Weak agonist Can stimulate T cell 
activation with higher doses 
as the wt antigen 
TCR antagonist Inhibits T cell activation when 
presented on the same APCs 
with the wt antigen 
Agonist Stimulates T cell activation 
at low doses 
  
APLs seem to influence the type and/or effectiveness of the T cell response by 
modulating the intracellular signal transduction pathways and phosphorylation of 
TCR-linked proteins involved in T cell activation (Abrams et al. 2000). APLs that act 
either as TCR antagonists or immune deviators have been studied in the murine 
model of multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). 
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The dominant antigen epitopes for these autoimmune diseases are quite well 
characterized. The use of APLs derived from the immunodominant epitopes has 
highlighted the possibility to induce a variety of biologic activities, such as cytokine 
production without proliferation, changes in cytokine profile, and anergy induction. 
Although the therapeutic APLs have been well studied in the experimental 
autoimmune diseases, there are still very few data available about the APLs 
application in the transplantation situation. 
Therefore, the aim of the study was to explore the possibility of modulating the 
alloimmune response using peptide analogues generated from the immunodominant 
MHC class I peptide. For this purpose, different Wistar-Furth MHC class I peptides 
(WF, RT1.Au), covering all the MHC different amino acids between WF (RT1u) as 
donors and LEW (RT1l) as recipients, were tested for their immunogenicity. Our 
results show the restriction of the alloimmune response to the immunodominant 
peptide P1 (residues 1-19). Since the disparities between P1 and the corresponding 
LEW sequence are located only on positions 5, 9, and 10, we changed these 
allogeneic amino acids step-by-step in order to generate peptide analogues. The 
“recipient-adapted” peptide analogues served as a useful tool to investigate the 
MHC-allopeptide-TCR interactions and, secondly, to modulate P1-induced T cell 
activation. One of the analogues, with one allogeneic position remaining, was able to 
reduce the P1-induced T cell proliferation and to inhibit the effect of P1 on the 
allograft survival time. The present results indicate that it is possible to generate 
analogues from the immunodominant allopeptide by changing the allogeneic amino 
acids with the corresponding syngeneic or self amino acids. Our findings underline 
the value of such analogues in analysing the fine specificity of the dominant 
allopeptide as well as their potential in the modulation of alloimmune responses. This 
could greatly facilitate the development of the particularly required antigen-specific 
strategies in transplantation.  
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2. AIMS OF THE STUDY 
1. Analyses of the immunogenicity of different MHC class I allopeptides from Wistar-
Furth (WF, RT1.Au) in Lewis (LEW, RT1.Al) recipients. Since the alloimmune 
response is induced by the MHC differences between donor and recipient, we 
analyzed whether there is a correlation between the MHC differences and their 
capacity to activate T cell alloimmune response resulting in allograft rejection.  
2. Generation of “recipient-adapted” peptide analogues from the immunodominant 
allopeptide by changing the allogeneic amino acids with the corresponding syngeneic 
amino acids. The analogues were tested for their ability to modulate the wild type 
peptide-induced alloimmune response. 
3. Analyses of the relationship between the modulatory ability of “recipient-adapted” 
peptide analogues and a specific TCR subpopulation. 
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3. MATERIALS AND METHODS 
3.1 Peptides 
Seven Wistar-Furth (WF) MHC class I (RT1.Au) peptides (P1-P7) were tested in the 
present study. The peptides were synthesized by MWG AG Biotech (München, 
Germany) and Jerini AG (Berlin, Germany) based on published sequences (Joly et 
al. 1995; Chowdhury et al. 1998). An additional 25-mer peptide (Pc, residues 110-
124) was used as a control peptide. Pc comprises a region of the MHC class I 
molecule in which both sequences are identical. The amino acid sequences are listed 
in a one-letter code in Figure 3. The peptides have a purity of 75 – 95% and bear an 
amide group at the C-terminal end. The lyophilized peptides were dissolved in sterile 
PBS at 1.0 mg/ml and stored at –20°C.  
FIGURE 3. Amino acid sequence alignment of WF (RT1.Au) and LEW (RT1.Al) MHC class I
molecules. For the RT1.Al, only the different amino acids are shown, dashes denoting identical
sequences. The sequences of the tested peptides are given below the alignment. The locations
on α-helical and β-plate regions are according to Bjorkman (Bjorkman et al. 1987). 
Wistar-Furth MHC class I - RT1.Au (Donor)
Lewis MHC class I - RT1.Al (Recipient)
α1 domain
GSHSLRYFLTAVSRPGLGEPRFIAVGYVDDTEFVRYDSDAENPRMEPRARWMEREGPEYWERETQGAKGHEQVNRVNLRTLRGYYNQSEG
----M---DI-----------Y-S-----H-----F--------Y----P-------D-------K---N--NYRVS-------------
GSHSLRYFLTAVSRPGLGE (P1)
PRFIAVGYVDDTE (P2)
AENPRMEPRARWMEREGPEYW (P3)
WERETQGAKGHEQVNRVNLRTLR (P4)
RT1.AU
RT1.Al
1 10 20 30 40 50 60 70 80
2 14 20 27 32 37 44 48 50 55 58 84 90
β-plate β-plate β-plate β-plate α-helix α-helix
α2 domain
RT1.AU
RT1.Al
GSHTIQVMFGCDVGTDWSLLRGYRQDAYDGRDYIALNEDLKTWTAADFAAQITRNKLERDGDADYYKAYLEGTCLESVRRYLELGKERLLRS
------R-Y-------G---------------------------------------WD-A—V—ERLR-------V—WL-----H---T---L
HTIQVMFGCDVGTDWSL (P5)
LRGYRQDAYDGRDYI (Pc)
RNKLERDGDADYYKAYL (P6)
GTCLESVRRYLELGKERL (P7)
91 100 110 120 130 140 150 160 170 180
92 104
β-plate 
112 118 124 127 132 136 138 148 151 161 163 173 175 180 182
β-plate β-plate β-plate α-helix α-helix α-helix α-helix
90
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The peptides are located in both the β-plate and the α-helix of either the α1 or α2 
domain of the RT1.Au molecule (Table 2) and cover almost all the MHC disparities 
between RT1.Au and RT1.Al molecules (29 from a total of 34 different amino acids). 
TABLE 2. Locations of the WF allopeptides (RT1.Au) on the MHC class I molecule 
Peptide Residues Location 
P1 1-19 β-plate, α1-domain 
P2 20-32 β-plate, α1-domain 
P3 40-60 β-plate, α1-domain 
P4 60-82 α-helix, α1-domain 
P5 93-109 β-plate, α2-domain 
P6 144-160 α-helix, α2-domain 
P7 166-179 α-helix, α2-domain 
Pc 110-124 β-plate, α2-domain 
The second set of experiments was performed using a series of 19-mer peptides, 
designed by amino acid substitution in the sequence of the peptide P1 (RT1.Au, 
residues 1-19). Peptide analogue Ac was used as the control peptide, having the 
identical amino acids as those of LEW (residues 1-19). The substitutions were made 
in positions 5, 9, and 10, in which the two MHC class I sequences are different. We 
generated the “recipient-adapted” peptide analogues (A1.1-A1.6) by changing the 
allogeneic RT1.Au amino acids with the corresponding syngeneic RT1.Al amino 
acids. The amino acid sequences of the peptide analogues are listed in Table 3. 
T
a
s
r
rABLE 3. Amino acid sequences of peptide analogues A1.1-A1.6 in one-letter code. For
nalogues, only the allogeneic RT1.Au amino acids (positions 5, 9, and 10) in comparison to the
yngeneic RT1.Al amino acids (residues 1-19) are shown (bold). The syngeneic amino acids are
epresented for control Ac. The underlined amino acids represent the MHC class II anchor
esidues as described by Rammensee et al. 1995 and extended by Wauben et al. 1997. Peptide Amino acid sequence 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
P1 (RT1.Au) G S H S L R Y F L T A V S R P G L G E 
A1.1 − − − − − − − − L T − − − − − − − − − 
A1.2 − − − − L − − − − T − − − − − − − − − 
A1.3 − − − − L − − − L − − − − − − − − − − 
A1.4 − − − − − − − − − T − − − − − − − − − 
A1.5 − − − − L − − − − − − − − − − − − − − 
A1.6 − − − − − − − − L − − − − − − − − − − 
Ac − − − − M − − − D I − − − − − − − − − 
RT1.Al  − − − − M − − − D I − − − − − − − − − 
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3.2 Animals 
Inbred male Lewis (LEW, RT1l) and Wistar-Furth (WF, RT1u) rats, 8-12 weeks old, 
weighing 150-200 g, were purchased from Charles River Germany GmbH (Sulzfeld, 
Germany). 
3.3 Immunization  
Lewis rats were subcutaneously immunized with 100 µg of the relevant MHC class I 
peptide (P1-P7) or the peptide analogue (A1.1-A1.6) emulsified with an equal volume 
of adjuvant (TiterMax, Alexis GmbH, Grünberg, Germany) into each hind footpad. For 
immunization, the animals were anaesthetized shortly with Isofluran (Abbott GmbH, 
Wiesbaden, Germany).  
3.4 Culture medium and buffers 
3.4.1 Culture medium 
The standard culture medium consists of RPMI 1640 medium supplemented with 20 
mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 5 x 10-5 M 2–mercaptoethanol, 1 % non-essential amino acids 
and 10 % fetal calf serum (FCS) (Life Technologies GmbH, Karlsruhe, Germany) as 
final concentrations. 
3.4.2 Lyse buffer (10-fold concentrated) 
The lyse-buffer used for the erythrolysis contains 1.68 M ammonium chloride, 99.88 
mM potassium hydrogen carbonate and 12.6 mM EDTA. As the buffer was 
concentrated 10-fold, it was diluted 1:10 with sterile aqua injectabila. 
3.4.3 Phosphate buffered saline (PBS) 
The phosphate buffered saline contains 140 mM sodium chloride, 2.7 mM potassium 
chloride, 7.2 mM sodium dihydrogen phosphate, 1.47 mM potassium dihydrogen 
phosphate and has a pH 7.2. 
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3.5 Proliferation assay  
3.5.1 Isolation of lymph node cells 
Popliteal lymph node cells were harvested 7 days after immunization of LEW rats 
with individual WF MHC class I peptides. The popliteal lymph nodes were prepared 
mechanically and the cells were washed twice and resuspended into 1 ml culture 
medium. 
3.5.2 Dendritic cells preparation 
Naïve LEW splenic dendritic cells (DCs) were used as self-APCs. Lewis rat spleens 
were aseptically removed into RPMI 1640 and the spleen cells were prepared 
mechanically. The resulting cell suspension was washed with culture medium. The 
erythrocytes were removed by resuspending the pellet into 10 ml 10-fold diluted lyse-
buffer, and the fluid fraction was washed with culture medium. The cell-pellet was 
incubated in petri dishes overnight in culture medium at 37 °C in a 5 % humidified 
CO2 atmosphere. The non-adherent cells were collected and DCs were isolated by 
centrifugation over a 14.5 % metrizamide gradient (Linaris Biologische Produkte 
GmbH, Wertheim, Germany) at 4 °C and 1823 xg for 13 minutes. The mononuclear 
cells were gently collected from the interface, washed with culture medium and 
resuspended in 1 ml culture medium. The prepared syngeneic DCs were irradiated 
with 20 Gray before using them as APCs. 
3.5.3 T cell proliferation assay 
A standard T cell proliferation assay was performed in 96-well rounded-bottom plates 
in order to investigate peptide immunogenicity. Primed T cells (105 cells/well) were 
cultured with irradiated syngeneic DCs (104 cells/well) and 5 µg/well peptide, into a 
final volume of 150 µl/well. Control wells were set up with control peptide Pc. Plates 
were incubated for 3 days at 37 °C in a 5 % humidified CO2 atmosphere and pulsed 
with 0.5 µCi/well [3H]-thymidine for the last 6 h of culture. The [3H]-thymidine 
incorporation was measured by using the standard liquid scintillation procedure. 
Experiments were set up in 6 replicates and results expressed in counts per minute 
(cpm) ± standard deviation (SD). 
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3.5.4 MHC competition assay 
Since the peptide analogues were generated to modulate the immune response, we 
performed a MHC competition assay, in order to test the ability of analogues to 
compete with the wild-type peptide P1 for the MHC binding sites. Therefore, 
syngeneic DCs (104 cells/well) were incubated with an optimal concentration of 
peptide P1 (5 µg/well) with a final volume of 100 µl/well. After 2 h, the P1-pulsed DCs 
were washed with culture medium to remove unbound peptides. Various 
concentrations of peptide analogues (1 - 100 µg/ml) were added and incubated for 
another 2 h into the same volume of 100 µl/well. The cells were washed again with 
culture medium and the P1-primed popliteal lymph node cells were added to the 
culture into a final volume of 150 µl/well. As controls, various concentrations of either 
P1 or Ac were added to P1-pulsed syngeneic DCs. The proliferation was assessed 
as previously described for a standard proliferation assay. 
3.5.5 TCR modulation assay 
Furthermore, in order to analyze whether the analogues are able to induce anergy or 
non-responsiveness in P1-specific T cells, P1-primed cells were incubated with 
different concentrations of peptide analogues (1 - 100 µg/ml) in the presence of 
syngeneic DCs into a final volume of 150 µl/well. After 2 h, cells were washed with 
culture medium and rechallenged with P1-pulsed syngeneic DCs. As controls, 
peptides P1 or Ac were added in the first step to P1-primed T cells and syngeneic 
DCs. The proliferation was measured as described for a standard proliferation assay. 
3.6 Measurement of cytokine production 
Culture supernatants of in vitro restimulated peptide-primed lymph node cells were 
collected after 72 h, and the levels of IL-2, IFN-γ, IL-4, IL-10 and IL-13 cytokines were 
assessed by ELISA method, using BioSource Cytoscreen kits (BioSource 
International, Camarillo, California, USA). The samples were added to the wells 
coated with a cytokine-specific antibody, followed by the addition of a biotinylated 
second antibody and, subsequently, the streptavidin-peroxidase. A 
tetramethylbenzidine solution was added to produce the color reaction, and its 
intensity was measured as optical density (OD) at 450 nm using an automated 
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ELISA-reader. The cytokine concentrations in the supernatant were expressed as 
pg/ml. 
3.7 Flow cytometry analysis 
5 x 105 cells/sample were incubated for 15 min at 4 °C with the optimal 
concentrations of mAbs in 100 µl of PBS. The following mouse anti-rat antibodies, 
conjugated with fluorescein isothiocyanate (FITC) or phycoerythrine (PE) were used 
for the analysis of cell surface molecules: W3/25 (anti-CD4), OX39 (anti-CD25), 
OX33 (anti-CD45RA, B cells), OX22 (anti-CD45RC) and R73 (anti-TCR αβ), and 
OX8 (anti-CD8α) (van den Berg et al. 2001). All antibodies were purchased by Linaris 
Biologische Produkte GmbH (Wertheim, Germany). The nonviable cells were 
identified with 7-amino actinomycin D (7-AAD) (Becton Dickinson, Mountain View, 
California, USA). Cell surface immunophenotypic analysis was performed by two-
color staining using the FACScan (Becton Dickinson, Mountain View, California, 
USA) with 10,000 gated cells. 
3.8 Heterotopic cardiac transplantation 
Lewis rats (LEW, RT1.Al) served as recipients and WF (RT1.Au) rats as donors. 
Heterotopic heart transplantation was performed according to the method of Ono and 
Lindsey (Ono et al. 1969) using standard microsurgical techniques. Briefly, the donor-
ascending aorta and the pulmonary trunk were anastomosed end-to-side to the 
recipient’s infrarenal abdominal aorta and inferior vena cava, respectively. The 
allograft function was monitored by daily transabdominal palpation of cardiac 
contractions. The rejection was considered complete at the time of cessation of 
palpable ventricular contractions. 
3.9 RT-PCR amplification of TCR Vß mRNA 
Total cellular RNA from 106 T cells, derived from popliteal lymph nodes or 
allotransplanted heart tissues, was extracted with 1 ml Trizol Reagent (Life 
Technologies GmbH, Karlsruhe, Germany) according to the manufacturer’s 
recommendations. The air-dried RNA was dissolved in 40 µl nuclease free water 
(Promega Corporation, Madison, WI, USA) and stored at –80° C. Graft-infiltrating 
lymphocytes (GILs) were isolated after perfusion of the cardiac grafts with cold saline 
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and subsequently mechanically minced. The cells were resuspended in culture 
medium; tissue debris was removed using a 100-µm strainer. For cDNA synthesis, 30 
µl RNA was reverse transcribed with MuLV reverse-transcriptase (2.5 U/µl) and Oligo 
d(T)16 primer (2.5 µM) using GeneAmp RNA PCR Kit (Applied Biosystems GmbH, 
Weiterstadt, Germany). Five µl cDNA was amplified using a digoxigenin (DIG)-
labeled TCR Cß1 primer (derived from the ß chain of the rat TCR constant region) as 
the downstream primer, and each one of the 22 different TCR Vß primers as the 
upstream primer into a final volume of 50 µl. All rat-specific primer sequences (TCR 
Cß1 and TCR Vß, respectively) were described by Shirwan (Shirwan et al. 1993) and 
are listed in Table 4. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
house-keeping gene, was used as control. The amplification products were 
separated on 2 % agarose gel to control the PCR reaction. The primers were 
synthesized by MWG Biotech AG (Ebersberg, Germany). 
TABLE 4. Oligonucleotide primers used for the analysis of TCR Vβ-chain genesa 
Primer Sequence (5' → 3') 
Cß1 AAG GGC CCA GCT CAG CTC CAC ATG GTC AAG  
Vß1 CCT GTC TTG TGG AAA CCG TAC  
Vß2 CTG GGG ACA AAG AGG TCA AAT C 
Vß3.3 GCT AGC AGG CTC TTT GGA TTG CC  
Vß4 TCT GGT GGC AGT CAC AGG GAG TG 
Vß5.2 GTG TGG CCT GGT ACC AAC AGA CTC  
Vß6 TCT CCT TGC AGT AGG AAC CAC AC 
Vß7 GAC CCA GAT CTG GGG CTA CGG 
Vß8.1 AGA GGT GAC ATT GAG CTG TCG 
Vß8.2 AAA GGT GAC ATT GAG TTG TAA G 
Vß8.3 AAA TGT GAC GTT CAA CTG TCA C 
Vß9 GGT TAT GCA GAA CCC AAG ATA 
Vß10 ATG TTT AGC TAC AAC AAT AAG C 
Vß11 ACA AAT GCT GGT GTC ATC CA 
Vß12 AGG GCC ACA ATG ATC TTT TC 
Vß13 GCA ATC ATA CAG GAA AGT CAG AC 
Vß14 TGG CAG GCT CCA GGA GGG ACC C 
Vß15 TCA CAC TGA GGG TGT TCA GGC C 
Vß16 GCA GGA CAC ACA GGA CCC AAC 
Vß17 GTA ACC CAG ACT CCA AGA TAC 
Vß18 TGT TGT TGA TAG TCA AGT TGC 
Vß19 AAG AAG CTG GGA GAA GAC CTC 
Vß20 TTT ACT TTC AGA ATC AAC GGC C 
a All the primers were published by Shirwan (Shirwan et al. 1993). 
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3.10 ELISA-based quantification of PCR products 
PCR amplicons were quantified using an ELISA-based method as described 
(VanderBorght et al. 1999). Briefly, 40 µl of PCR amplicons were denatured and 
hybridized with 0.5 mM biotinylated TCR Cß1 sonde (5’-TGG GTG GAG TCA CCG 
TTT TCA G-3’) for 30 min at 55 °C in a PCR cycler. Subsequently, 1 µl of the DNA 
hybrids was diluted with 50 µl hybridization buffer and transferred to a streptavidin-
coated nuclease-free microtiter plate. Finally, the captured amplicons were incubated 
with anti-DIG peroxidase conjugate and then detected with peroxidase substrate 
solution. The peroxidase reaction was stopped with 100 µl H2SO4. All reagents for the 
PCR-ELISA were purchased from Roche Diagnostics GmbH (Mannheim, Germany). 
The ELISA was carried out in duplicate and the reaction intensity was measured at 
450 nm (A450) using an automated ELISA-reader. The expression level of each Vß 
gene was calculated as the percentage of total Vß gene expression using the formula 
%Vßx = (A450 (Vßx) x 100 / Σ A450 (Vßn)). Three animals per group were tested. 
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4. RESULTS  
4.1 Investigation of regional lymph nodes after immunization 
Seven days after subcutaneous immunization with the immunogenic peptide P1 (see 
below), the popliteal lymph nodes were enlarged and the cell number was increased 
(12.3 ± 2.7 x 107 cells), in comparison to naïve LEW (3.3 ± 1.4 x 107 cells) (Figure 4). 
The immunization was performed with TiterMax as immune adjuvant; taken alone it 
was not able to increase the number of lymph node cells (2.5 ± 0.8 x 107 cells). 
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FIGURE 4. The number of lymph node
cells increased after immunization
with the immunogenic peptide P1. The
immune adjuvant TiterMax had no
influence. Bars represent the mean (±
SD) of three animals per group. C
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In order to investigate T cell activation after immunization, lymph node cells were 
analyzed for the expression of CD25 (IL-2Rα) molecules as an activation marker 
using flow cytometric analysis (FACS). As shown in Figure 5 (A), the proportion of 
CD4+ CD25+ T cells increased to only 5.5 % after immunization with allopeptide P1 
(A) Pc-primed  P1-primed Naïve 
FIGURE 5. Cells were
double-stained with anti-
CD4 (W3/25) and anti-CD25
(OX39) mAbs and analyzed
by flow cytometry. (A) The
proportion of activated
CD4+ T cells in the
regional lymph nodes
increased moderately,
while (B) the total number
of activated T cells
increased markedly after
immunization with the
immunogenic peptide P1. 
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in comparison to naïve LEW cells (3.8 %). The total number of cells in the lymph 
nodes of P1-immunized animals increased about 3-fold in comparison to naïve cells, 
consequently the number of activated CD4+ T cells increased about 6-fold in this 
situation (Figure 5 (B)). It is noteworthy that immunization with peptide Pc had no 
influence on the activated T cell population when compared to naïve cells. These 
results indicate that the subcutaneous immunization with an immunogenic allopeptide 
is able to activate the immune system of recipients as demonstrated by the enlarged 
lymph nodes with elevated total cell-numbers as well as activated CD4+ T cells. 
Next, the allopeptide-primed lymph node cells were analyzed for the distribution of 
different populations. As shown in Figure 6, the fraction of T cells slightly decreased 
after immunization (63.7 % to 54.4 %), while the CD4+ / CD8+ T cell ratio was not 
affected by the immunization (range 2.6 – 2.9). In contrast, the percentage of B cells 
increased after immunization, from 27.8 % in naïve lymph node cells to 40.3 % in the 
allopeptide-immunized animals. These results indicate that both T cells, as shown by 
the increased number of CD25+ CD4+ T cells and B cells, as shown by the increased 
cell number, are activated as a response to immunization. This indicates that 
immunization seems also to activate the humoral response. 
 
 (A) Naïve cells 
FIGURE 6. Flow-cytometric
analysis (FACS) of the effect of
immunization with allopeptides on
the distribution of the different
lymph node cell populations. (A)
Naïve lymph node cells and (B)
peptide-primed cells were stained
with anti-TCR αβ (R73), anti-
CD45RA (OX33), anti-CD4 (W3/25),
and anti-CD8 (OX8) mAbs. After
immunization, the proportion of B
cells increased, In addition, the
CD4+ / CD8+ T cell ratio was
unmodified after immunization.  
CD4+ T cells
B cells
CD8+
Other cells
T cells CD4+ 
CD8+ 
B cells
Other cells
54.4% 40.3% 
 (B) Peptide-primed cells 
63.7%
27.8% 
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4.2 Determination of the optimal conditions for the T cell proliferation assay 
First, we addressed the following questions: what are the parameters of choice for 
the T cell proliferation assay in regard to incubation time, necessity of primed T cells, 
and optimal antigen concentration used for restimulation. To establish this, different 
amounts of peptide-primed T cells isolated 7 days after immunization were incubated 
in vitro with syngeneic DCs and different concentrations of peptides. The cells were 
pulsed with [3H]-thymidine after 24 h, 48 h, 72 h, and 96 h, respectively. As shown in 
Figure 7 (A), peptide P1 induced the highest proliferation when 105 P1-primed T cells 
were restimulated (21,300 ± 2,500 cpm). This effect was not evident in the control 
peptide Pc and peptide P3, both having low proliferation capacity (see below). 
Furthermore, the maximum proliferation was induced by 25 µg/ml of peptide (23,500 
FIGURE 7. Selection of the optimal conditions for the proliferation assay. (A) The highest T cell
proliferation was obtained with 105 T cells. (B) The maximum proliferation was induced by 25
µg/ml antigen and (C) after 72 h incubation. Results represent the mean (± SD) of 6 replicates
from three animals per group. 
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± 2,100 cpm for P1 and 8,570 ± 1,800 cpm for P3). The proliferative response 
decreased when peptides were added at high concentration (100 µg/ml) to 8,350 ± 
1,400 cpm for P1 and 4,500 ± 1,100 cpm for P3 (Figure 7 (B)). The next parameter 
for testing was the incubation time. After 72 h of incubation, the proliferation showed 
the highest values for peptides P1 (22,450 ± 2,300 cpm) and P3 (6,700 ± 1,600 cpm), 
respectively, while Pc as control was not influenced (Figure 7 (C)). To summarize, 
the T cell proliferation assay established in our laboratory requires 105 peptide-
primed T cells, which should be restimulated with 25 µg/ml peptide for 72 h. These 
conditions represent the standard parameters for the next experiments. 
4.3 Immunogenicity of donor MHC class I allopeptides 
Next, we addressed the question of whether the MHC differences between WF as 
donors and LEW as recipients are reflected by the immunogenicity of allopeptides. 
Seven WF MHC class I allopeptides (RT1.Au, P1-P7), covering 29 from a total of 34 
allogeneic amino acids (Figure 3) were tested in LEW (RT1l) rats using the T cell 
proliferation assay. T cell proliferation to the individual peptides was considered 
positive, and the respective peptide as immunogenic, when the [3H]-thymidine 
incorporation was higher than 2,000 cpm, corresponding to the 2-fold mean value of 
the Pc-induced proliferation (Figure 8). The peptide-primed T cells showed a 
hierarchical distribution of specific proliferation with high values for the peptides 
FIGURE 8. Hierarchical distribution 
of the proliferative responses to 
individual WF MHC class I peptides 
(RT1.Au). Lewis rats were 
immunized with individual WF MHC 
class I peptides. Peptide P1 induced 
the strongest proliferation and 
represents the dominant peptide. 
P2-P5, inducing lower proliferation, 
are considered subdominant 
peptides, while P6 and P7 are non-
immunogenic in LEW rats. Results 
represent the mean (± SD) of 6 
replicates from 3 animals per group.
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P3
P4
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Proliferation (x 1,000 cpm) 
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located in the α1 domain (P1-P4) and lower for those derived from the α2 domain 
(P5-P7), although the number of allogeneic amino acids is equally distributed 
between the two domains (Figure 3). Thus, five of the seven WF MHC class I 
peptides were immunogenic after immunization of LEW rats (P1-P5). In addition, 
peptide P1, which covers 3 allogeneic amino acids, induced the strongest T cell 
proliferation (21,500 ± 1,137 cpm). Peptides P2 and P3, each comprised of three 
allogeneic positions, induced a lower proliferative response (5,500 ± 400 cpm, and 
7,600 ± 300 cpm). The other immunogenic peptides, P4 and P5, induced a limited 
proliferation of the primed T cells (3,200 ± 200 cpm and 2,900 ± 230 cpm), although 
peptide P4 contains 7 different amino acids in comparison with the LEW sequence 
(Figure 3). Moreover, peptides P6 and P7, with 8 and 5 allogeneic positions, were not 
able to induce specific proliferation in LEW rats. These results indicate that the 
immunogenicity is not influenced by the number of MHC disparities, but possibly by 
their quality. While in the WF-LEW rat strain combination four (P1-P4) of the five 
immunogenic peptides are located on the α1-domain, it seems that this domain is 
more important for the induction of the alloimmune response in our model. In 
conclusion, the WF MHC class I peptide P1 represents the dominant allopeptide for 
the LEW alloreactive T cells, peptides P2-P5 are subdominant, and P6 and P7, are 
non-immunogenic peptides (Table 5). 
TABLE 5. The immunogenicity of MHC class I peptides does not correlate with the number of
allogeneic amino acids. Four (P1-P4) out of the five immunogenic peptides are located on the
α1-domain . 
Peptides MHC location Allogeneic 
amino acids  
Immunogenicity 
P1 α1-domain 3 Dominant 
P2 α1-domain 3 Subdominant 
P3 α1-domain 3 Subdominant 
P4 α2-domain 7 Subdominant 
P5 α2-domain 3 Subdominant 
P6 α2-domain 8 Non-immunogenic 
P7 α2-domain 5 Non-immunogenic 
Pc α2-domain 0 Control 
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Next, we examined whether the induction of specific T cell proliferation correlates 
with the cytokine production. The supernatants of peptide-primed T cell cultures were 
collected after 72 h of incubation. The dominant peptide P1 induced markedly higher 
levels of IL-2 (11-fold increase), IFN-γ (139-fold increase), IL-10 (2.4-fold increase) 
and IL-13 (15-fold increase) in comparison to the control peptide Pc (Table 6). The 
immunogenic peptides P2-P5 (see also Figure 8) induced increased levels of IFN-γ, 
while the IL-2 production was limited (56-76 pg/ml). Interestingly, peptide P4 with a 
low proliferation capacity induced high levels of IFN-γ (253 pg/ml). Since peptides P6 
and P7 lack proliferation, the cytokine production induced by these peptides were 
considered as background. P1 with only 3 allogeneic amino acids, represents the 
dominant peptide, inducing the strongest T cell proliferation with the highest cytokine 
levels.  
TABLE 6. Cytokine production induced by the individual WF MHC class I peptides after in vivo 
immunization and specific in vitro restimulation of the primed T cells. Results represent the 
mean (± SD) of duplicates from two animals per group. 
Cytokines (pg/ml) P1 P2 P3 P4 P5 P6 P7 Pc 
IL-2 278±19 76±4 62±20 74±16 56±3 36±12 33±1 18±1 
IFN-γ 1,802±269 160±4 77±17 253±10 61±6 37±1 32±2 13±4 
IL-4 6±1 3±1 6±1 6±1 16±3 2±1 3±1 1±1 
IL-10 97±8 41±5 91±5 87±5 36±2 25±1 14±1 40±4 
IL-13 192±6 15±2 87±3 91±3 65±1 30±4 40±5 13±1 
4.4 Evidence for immunodominance between MHC class I allopeptides 
In order to confirm the immunodominance of peptide P1, LEW rats were immunized 
with a mixture of 5 allopeptides having different immunogenicities: 3 immunogenic 
(P1, P2 and P3), 1 non-immunogenic (P6), and the control peptide Pc (Figure 9). The 
primed lymph node T cells were restimulated in vitro with the individual peptides in 
the presence of syngeneic DCs. Peptide P1 was able to induce the strongest 
proliferation of mixture-primed T cells (22,350 ± 1,800 cpm). Peptides P2 and P3, 
which also consist of 3 allogeneic positions, had only a minimal proliferation effect 
(2,400 ± 500 cpm and 2,900 ± 500 cpm). There was no proliferative response when 
cells were restimulated with the non-immunogenic peptide P6 (1,400 ± 200 cpm) or 
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FIGURE 9. T cell proliferation
after immunization with a
mixture of P1, P2, P3, P6 and Pc.
The primed T cells proliferated
stronger against P1, while P2
and P3 induced a limited
proliferation, confirming the
dominance of P1. Bars
represent the mean (± SD) of 6
replicates from 2 animals per
group. 
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the control peptide Pc (1,200 ± 300 cpm). Since P1 was able to induce the strongest 
T cell proliferation of individual peptide-primed T cells as well as of peptide mixture-
primed T cells, the results confirm the dominance of peptide P1 in LEW responders. 
 
 4.5 Specificity of P1-primed T cells  
In order to test the specificity of P1-primed T cells for the other MHC class I peptides, 
we analyzed the proliferation of P1-primed T cells in the presence of each of the 
seven synthetic peptides (P1-P7). As shown in Figure 10, only the immunogenic 
peptides P2 and P3 were able to induce a weak proliferation of P1-primed T cells 
(4,200 ± 890 cpm and 6,700 ± 1,200 cpm). Noteworthy is that these two peptides 
also induced a strong proliferation of specific T cells (Figure 8). Peptides P4-P7 failed 
to induce a proliferative response of the P1-primed T cells (< 2,000 cpm). These 
results show that there is less cross-reactivity between the P1-primed T cells and 
other allopeptides. This is unconstrained by the number of allogeneic positions 
covered by the peptides, but eventually by their specific immunogenicity. This finding 
FIGURE 10. Specificity of
P1-primed T cells for
MHC allopeptides. Only
P2 and P3 were able to
induce proliferation of
P1-primed T cells. The
other MHC class I
peptides failed to activate
such T cells. 
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indicates the specificity of the cells primed during immunization with the 
immunodominant peptide P1 in our system. 
4.6 Recognition of donor MHC class I peptides is MHC class II-restricted 
In order to investigate the importance of MHC class I or class II molecules for the 
presentation of synthetic MHC class I peptide in the in vitro proliferation assay, we 
performed an antibody blocking assay. P1-primed T cells were incubated with 
syngeneic DCs and peptide P1 in the presence of different antibodies. As shown in 
Figure 11, the proliferation of P1-primed T cells was markedly reduced in the 
presence of anti-MHC class II (OX6, anti-RT1.B) (8,680 ± 1,200 cpm) as well as anti-
CD4 (W3/25) (6,150 ± 2,200 cpm) antibodies, whereas anti-MHC class I (OX18, anti-
RT1.A) and anti-CD8 (OX8) antibodies did not influence the T cell proliferation.  
FIGURE 11. Antibody blocking 
assay for P1-primed T cells. P1-
primed T cells failed to 
proliferate in the presence of 
anti-CD4 (10 µg/ml) and anti-
MHC class II (12.5 µg/ml) mAbs 
in the in vitro proliferation
assay. Control wells were set 
up with 12.5 µg/ml of irrelevant 
IgG antibody. 
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4.7 Effect of immunization with MHC class I allopeptides on allograft survival 
To test whether the in vitro findings are of importance in the in vivo transplantation 
situation, the effect of an immunization with donor MHC class I peptides on the 
allograft survival time was analyzed in a heterotopic cardiac transplantation model 
between WF rats (RT1u) as donors, and LEW rats (RT1l) as recipients. The animals 
were divided into the following groups: control group, composed of either non-
immunized or WF skin-transplanted LEW recipients, the P1 group, composed of P1-
immunized LEW recipients, and 3 additional groups consisting of P3, P7, and Pc 
immunized LEW recipients (Figure12 (A)). Another group consisted of LEW 
recipients, which received P1-primed lymph node cells 7 days before transplantation 
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(Figure 12 (B)). None of the transplanted animals received immunosuppressive 
therapy before or after transplantation. The non-immunized animals rejected their 
allografts within 8 days after transplantation, while those animals that received WF 
skin grafts (the strongest sensitization procedure), induced an accelerated rejection 
of heart allografts within 48 h. Immunizing with the control peptide Pc or non-
immunogenic peptide P7 had no influence on the allograft survival time. Surprisingly, 
peptide P3 with a low T cell proliferation and cytokine production was able to 
significantly reduce the cardiac allograft survival time to 5.5 ± 0.5 days, comparable 
to the dominant peptide P1 (4.5 ± 0.5 days). Furthermore, the transfer of P1-primed T 
cells into LEW recipients induced the same effect on the allograft (5.3 ± 0.5 days), 
confirming the in vitro dominance of these cells. In conclusion, immunization with WF 
peptide P1, covering only 3 allogeneic amino acids, seems to be able to activate the 
alloimmune system of LEW recipients as confirmed by in vitro proliferation and 
cytokine production of P1-primed T cells as well as by the reduction of allograft 
survival time.  
 
(A) FIGURE 12. (A) Immunization
with the immunogenic peptides,
P1 or P3 reduced the allograft
survival time. The WF skin-
transplanted (STx) recipients
rejected their grafts within the
first 48 h after transplantation.
The non-immunized control
animals, and the animals
immunized with P7 or Pc,
d their grafts within 8
days. (B) The transfer of P1-
primed T cells into naïve LEW
recipients induced the rejection
of allografted hearts within 5
days, comparable to the
immunization with P1.  
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Summary 4.1 – 4.7: Not all the tested WF MHC class I peptides (RT1.Au) were 
immunogenic in the LEW (RT1.Al) recipients. There was a hierarchical distribution of 
their immunogenic abilities, as shown by the in vitro proliferation assay. Almost all of 
the immunogenic peptides are located on the α1 domain of a MHC class I molecule, 
but the immunogenicity was unconstrained by the number of covered allogeneic 
amino acids. In addition, peptide P1, comprised of only 3 allogeneic amino acids, 
induced the strongest T cell proliferation and produced high levels of cytokines, 
especially IL-2 and IFN-γ. Furthermore, the immunodominance of peptide P1 was 
confirmed by the significant reduction of the allograft survival time in the heterotopic 
heart transplantation model. 
Introduction 4.8 – 4.13: Since the first set of experiments demonstrated the central 
role of the immunodominant MHC class I allopeptide P1 in the induction of an 
alloimmune response, the next step was to design “recipient-adapted” peptide 
analogues derived from peptide P1. The analogues were designed by changing step 
by step the allogeneic RT1.Au (non-self) amino acids with the corresponding 
syngeneic RT1.Al (self) amino acids on the three different positions 5, 9, and 10. The 
six analogues were further analyzed for their ability to modulate the alloimmune 
response 
4.8 Kinetic and dose-dependent proliferation induced by peptide analogues 
First, we tested whether the proliferation responses induced by the peptide 
analogues follow the optimal conditions established for the MHC class I peptides. 
The analogue-induced proliferation was assessed after different incubation times (24, 
48, 72, 96, and 120 h). After 72 h of in vitro restimulation, almost all the analogues 
(A1.1-A1.4, and A1.6) showed a maximum proliferation, whereas the analogue A1.5 
induced the maximum proliferation after 96 h (44,290 ± 4,200 cpm) (Figure 13 (A)). In 
addition, the proliferative responses induced by the analogues A1.1 and A1.5 were 
dose-dependent (Figure 13 (B)). As a control analogue, Ac was not able to induce a 
proliferative response (4,500 ± 420 cpm) and its values were not influenced by the 
incubation time or the peptide doses used for the restimulation, as it was recognized 
as a self-peptide.  
 
   25 
(A) (B) 
0
20
40
60
10050256.251.56
P1 (wt) A1.1 A1.5 Ac
0
20
40
60
24h 48h 72h 96h 120h
P1 (wt) A1.1 A1.5 Ac
Pr
ol
ife
ra
tio
n 
(x
 1
,0
00
 c
pm
) 
Pr
ol
ife
ra
tio
n 
(x
 1
,0
00
 c
pm
) 
Incubation time Peptide concentration (µg/ml) 
 
FIGURE 13. (A) Kinetic analysis of T cell proliferation. Analogue A1.1 and peptide P1 induced
the maximum proliferation after 72 h of incubation, while analogue A1.5 reached its maximum
after 96 hours. (B) The analogues A1.1 and A1.5 induced a dose-dependent specific T cell 
proliferation. 
4.9 Characterization of peptide analogue-primed T cells 
First, the peptide analogues A1.1–A1.6 were tested whether single or double 
substitutions have any influence on the proliferative response. Analogue Ac, 
corresponding to LEW sequence (residues 1-19) was used as a control. The 
individual analogues were analyzed in a standard proliferation assay of analogue-
primed lymph node T cells. When compared to the wt peptide P1-induced T cell 
proliferation, the analogues can be categorized into three groups (Figure 14): (a) The 
analogue A1.1 with 2 allogeneic amino acids (L9, T10) and a substituted amino acid 
(L5 with M5), which induced a stronger T cell proliferation (45,098 ± 2,600 cpm) than 
P1. (b) The analogue A1.5, containing the residue L5 as the only allogeneic amino 
acid, which had a weaker specific proliferation capacity (11,450 ± 1,400 cpm) in 
comparison to P1; and (c) the other analogues (A1.2-A1.4, and A1.6), which were 
able to induce a specific proliferation comparable with peptide P1. These results 
show that the analogues with given substitutions are able to induce a specific 
proliferative response and these proliferations depend on the position where the 
substitution was made. 
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FIGURE 14. Peptide 
analogues have different 
specific proliferative capacity. 
The allogeneic amino acids 
are shown on the left side.
A1.1 (two allogeneic amino 
acids) induced a stronger 
proliferation, whereas A1.5 
(one different amino acid) 
induced a weaker proliferative 
response in comparison to 
P1. Bars represent the mean 
(± SD) of 6 replicates from 3 
animals per group. 
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In order to further characterize the activation capacity of the analogues, the cytokine 
production was measured in the supernatant of 72 h-cultures of analogue-primed T 
cells (Table 7).  
TABLE 7. Cytokine production by peptide analogue-primed T cells. Cytokine levels were 
measured by ELISA in the 3-day culture supernatants. Data are mean values (± SD) of 
duplicates from 3 animals per group. 
Cytokine levels (pg/ml) 
Peptide IL-2 IFN-γ IL-4 IL-10 IL-13 
P1 278±19 1,802±269 6±1 97±8 192±6 
A1.1 2,172±28 9,270±170 4±0,3 221±48 161±31 
A1.2 755±36 877±63 18±5 41±12 80±21 
A1.3 558±59 553±49 10±1 75±36 306±36 
A1.4 163±16 535±69 279±25 80±20 261±45 
A1.5 485±42 1404±56 344±68 172±13 49±3 
A1.6 422±21 390±25 1±0.1 138±25 26±9 
Ac 40±5 60±6 1±0.1 36±8 22±4 
 
All analogues except A1.4 induced higher levels of IL-2 in comparison to the wt 
peptide P1, indicating that there is no correlation between the specific proliferation 
and IL-2 production. Analogue A1.1 with the L9, T10 allogeneic amino acids induced 
the highest levels of IL-2, IFN-γ, IL-10 and IL-13. Interestingly, analogues with one 
allogeneic position, which induce the same specific T cell proliferation as P1, are able 
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to produce an altered cytokine profile: e.g. A1.4 (T10) induced lower levels of IL-2 
and IFN-γ (163 ± 16 pg/ml, and 535 ± 69 pg/ml) but elevated levels of IL-4 and IL-13 
(279 ± 25 pg/ml, and 261 ± 45 pg/ml). In contrast, the analogue A1.5, with weaker 
specific proliferation ability, induced a high level of IFN-γ (1,404 ± 56 pg/ml) similar to 
P1, associated with increased IL-4 and IL-10 secretions. These data underline the 
implication of each allogeneic position in the activation of the specific T cells. 
Altogether, the generated analogues are able to induce a specific immune response 
characterized by specific proliferation and cytokine production (Table 8). 
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oABLE 8. Relationship between the specific proliferation and cytokine production and the
llogenicity of the peptide analogues. Peptide Allogenicitya Specific proliferationb Specific cytokinesc 
P1d L L T 3   
A1.1 − L T 2 > IL-2, IFN-γ, IL-10 
A1.2 L − T 2 = IL-2, IL-4 
A1.3 L L − 2 = IL-2, IL-4, IL-13 
A1.4 − − T 1 = IL-4, IL-10, IL-13 
A1.5 L − − 1 < IL-2, IFN-γ, IL-4, IL-10 
A1.6 − L − 1 = IL-2, IL-10 
Ace M D I 0 No No 
Allogenicity corresponds to the number of allogeneic amino acids for each analogue. Only the three 
ifferent positions (5, 9, and 10) are shown. 
The specific proliferative capacities are qualitatively expressed as high (> P1), low (< P1), or equal (= 
1) in comparison to the wt peptide P1 (21,500 ± 1,137 cpm). 
Each cytokines level is compared to the level produced by P1: IL-2 > 278±19 pg/ml, IFN-γ > 
,802±269 pg/ml, IL-4 > 6±1 pg/ml, IL-10 > 97±8 pg/ml, and IL-13 > 192±6 pg/ml. Only the cytokines 
hat fulfill these values are shown. 
P1 is the wt peptide with three allogeneic amino acids. 
Ac is the peptide with syngeneic sequence. 
s shown in Table 8, the number of allogeneic amino acids does not correlate with 
he intensity of the proliferative response, whereas the substitutions made on these 
ositions give us some indication of their importance in the MHC-peptide-TCR 
nteraction. Thus, when L5 is not substituted and one of the amino acids on position 9 
r 10 is modified (A1.2, A1.3), the resulting peptides have the same proliferation 
   28 
ability as P1, whereas A1.1 with modified L5 induced a higher proliferation than P1. 
These data correlate with the finding described by Rammensee (Rammensee et al. 
1995) and extended by Wauben (Wauben et al. 1997) that L5 represents a possible 
MHC anchor residue. The substitution of L5 with M5 induced a higher proliferation 
(A1.1), probably caused by the higher MHC binding affinity of methionine. 
Furthermore, analogue A1.5 with only one allogeneic amino acid (L5) induced a 
lower proliferation in comparison to P1. As a whole, these results indicate that 
position 5 is important for the MHC contact, while the other two positions (9 and 10) 
could be important for TCR contact.  
4.10 Specificity of peptide P1-primed T cells for its peptide analogues 
Since the analogue-primed T cells showed a different proliferative capacity, the next 
question was whether the specificity of P1-primed T cells is influenced by these 
substitutions. Therefore, P1-primed T cells were restimulated in vitro with peptide 
analogues based on the standard proliferation assay. As shown in Figure 15, P1-
primed T cells were able to proliferate in the presence of the analogues A1.1 (L9, 
T10) and A1.6 (L9) (36,200 ± 2,400 cpm and 27,900 ± 3,100 cpm, respectively). 
Analogues A1.2, A1.3, and A1.4 induced a lower proliferation of the P1-primed T 
cells in comparison to P1 (9,350 – 16,100 cpm), indicating that single changes on 
positions 9 or 10 still allow the activation of the P1-primed T cells, but at a lower level. 
In addition, the P1-primed T cells failed to proliferate in the presence of A1.5 (3,800 ± 
1,500 cpm), comparable to the syngeneic peptide Ac (3,250 ± 1,200 cpm). This 
finding indicates that the double substituted analogue A1.5, with unmodified MHC 
FIGURE 15. Specificity of P1-
primed T cells for the
analogues. P1-primed T cells
were restimulated in vitro with
the peptide analogues and
syngeneic DCs. A1.5 and the
control Ac failed to induce
proliferation of P1-primed T
cells. Bars represent the
mean (± SD) of 6 replicates
from 3 animals. 
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contact (L5), either down-regulated P1-induced activation or the peptide was not 
recognized by P1-primed T cells. Following the classification described by Anderton 
(Anderton 2001) (Table 1), the analogues could be categorized as follows: A1.1 as 
agonist, A1.6 as agonist and A1.2, A1.3, and A1.4 as weak agonist peptides. 
Analogue A1.5 was able to down-regulate the proliferation of P1-primed T cells.  
4.11 TCR modulation ability 
Next, we performed a TCR modulation assay in order to investigate the mechanism 
responsible for the lack of proliferation of P1-primed T cells induced by analogue 
A1.5. The schematic presentation of the assay is shown in Figure 16.  
FIGURE 16. TCR modulation assay.
P1-primed T cells were incubated
for 2 h with various concentrations
of analogues and syngeneic DCs.
After 2 h, P1-pulsed DCs were
added and the proliferation of P1-
primed T cells was measured as
described for the standard
proliferation assay. 
+ 
wt peptide 
P1 
Syngeneic
DCs 
P1-primed 
T cells 
P1-pulsed 
DCs
2h 
Proliferation Analogue 
Figure 17 shows that the P1-primed T cells, pre-incubated with either the control 
peptide Ac (33,900 ± 2,700 cpm for 10 µg/ml) or the wt peptide P1 (30,600 ± 2,900 
cpm), were able to proliferate after the second in vitro rechallenge with P1. Pre-
incubation of P1-primed T cells with analogue A1.5 did not influence the proliferation 
after the restimulation (29,500 ± 2,200 cpm for A1.5 vs. 30,600 ± 2,900 cpm when 
FIGURE 17. TCR modulation
assay. P1-primed T cells pre-
incubated with A1.5 proliferated
after rechallenge with P1,
indicating that A1.5 did not
induce anergy or other permanent
negative signals in P1-primed T
cells. Results represent the mean
(± SD) of 6 replicates from 2
animals per group. 
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cells were pre-incubated with 10 µg/ml peptide). This finding indicates that A1.5 did 
not induce a state of non-responsiveness in P1-primed T cells through the T cell 
receptor (Figure 15). 
4.12 Analogue A1.5 acts as a MHC competitor 
The next question we addressed was whether A1.5 is able to compete with the wt 
peptide P1 for the MHC binding. For this purpose we performed a MHC competition 
assay as presented in Figure 18.  
P1 
P1 
Self-DCs 
Analogue
P1-primed 
T cells 
P1-pulsed 
DCs 
2 h 
FIGURE 18. Schematic presentation of
the MHC competition assay. Syngeneic
DCs were pulsed with P1 and after 2 h
various concentrations of analogues
were added in order to compete for the
MHC binding. After 2 h, proliferation of
P1-primed T cells was measured as
described for the standard proliferation
assay.
Proliferation
Control peptide Ac did not influence the proliferation of P1-primed T cells, showing a 
similar dose-dependent proliferation to P1 (Figure 19). While at a concentration of 
100 µg/ml the proliferation of P1-primed T cells seems to show a high-dose inhibition, 
only the lower concentrations were considered significant. The analogue A1.5 was 
able to reduce the proliferation when added at 1 and 10 µg/ml (14,461 ± 2,100 cpm 
vs. 30,200 ± 2,900 cpm for P1). These results indicate that A1.5 with only one 
allogeneic position acts as a MHC competitor.  
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FIGURE 19. MHC competition
assay. A1.5 reduced the
proliferation of P1-primed T
cells when presented on the
same DCs. The data indicate
the competition of A1.5 with the
wt peptide P1 for MHC binding.
Results represent the mean (±
SD) of 6 replicates from 2
animals per group. Competitor peptides (µg/ml) 
   31 
4.13 Influence of peptide analogues on the allograft survival time 
Since the previous experimental results demonstrated that in comparison to P1, 
analogue A1.5 had weak proliferation ability and A1.1 stronger proliferation ability, 
these two analogues were further investigated for their in vivo effect in the allograft 
situation (Figure 20). Lewis rats were immunized with individual peptide analogues 7 
days before they received a heterotopically transplanted WF heart. A1.1-immunized 
animals rejected their allografts within 5 days (5.2 ± 0.5 days) similar to the wt 
peptide P1-immunized recipients (4.5 ± 0.5 days). In concordance with the low T cell 
proliferation induced by the analogue A1.5, this peptide had no influence on the 
allograft survival time when compared to the control group, non-immunized recipients 
(8.8 ± 0.5 days). Furthermore, when LEW recipients were immunized with a mixture 
composed of equal amounts of P1 and A1.5, the allograft was rejected after 7.7 ± 0.6 
days. These results can be explained by the MHC competition between A1.5 and P1, 
as shown by the MHC competition assay (Figure 19), i.e. A1.5 was able to diminish 
the negative effect of P1 on the allograft survival.  
 
FIGURE 20. Allograft survival
time induced by the
immunization with peptide
analogues (n = 4 animals per
group). A1.1 reduced the
allograft survival time similar
to peptide P1, whereas A1.5
had no influence.
Immunization with a mixture
of P1 and A1.5 prevented the
P1-induced reduction of
raft survival time. allog0 2 4 6 8 10
Control
P1 
A1.1
A1.5
P1 + A1.5
Days posttransplantation
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Summary 4.8 – 4.13: The “recipient-adapted” peptide analogues were designed by 
changing the allogeneic RT1.Au amino acids one by one with the syngeneic RT1.Al 
amino acids, from the RT1.Au immunodominant peptide P1 as wild-type peptide. The 
six analogues containing such substitutions were tested in a standard proliferation 
assay for their ability to induce a specific immune response. Our results indicate that 
position 5 may be MHC anchor, while the other two allogeneic positions (L9, T10) are 
important for the TCR contact (Table 8, Figure 15). Next, the analogues were tested 
for their capacity to activate the wt peptide P1-primed T cells. Following the 
classification described by Anderton (Anderton 2001), analogues A1.1 and A1.6 are 
agonists, and A1.2, A1.3, and A1.4 weak agonist peptides, while A1.5 could be 
classified as a partial agonist or TCR antagonist. Further experiments demonstrated 
that A1.5 acts as a MHC competitor. The in vitro characteristics of A1.5 were 
confirmed by the in vivo experiments. Immunization with A1.5 does not influence the 
allograft survival time but does diminish the negative effect of the wt peptide, 
probably by competing for the MHC binding as showed in the MHC competition 
assay. In conclusion, “recipient-adapted” peptide analogues, such as A1.5, are able 
to down-regulate the alloimmune response induced by the dominant allopeptide P1 
by a MHC competition mechanism. 
Introduction 4.14 – 4.17: The next set of experiments was performed in order to 
characterize the TCR Vß repertoire of the peptide-primed T cells after immunization, 
in vitro restimulation and allotransplantation. Since the allopeptide in the MHC-
peptide-TCR complex exclusively contacts the TCR β chain (Qadri et al. 2001), the 
TCR Vß usage was analyzed using RT-PCR ELISA-based method.  
4.14 TCR Vß repertoire of MHC class I allopeptides-primed T cells  
First, we addressed the question whether the immunogenicity of the tested 
allopeptides is associated with a defined TCR Vß repertoire after immunization. The 
percentage expression of TCR Vß genes in the Pc-primed cells was used as control. 
The TCR Vß repertoire of freshly isolated T cells primed after immunization with self-
peptide Pc showed minimal differences from the naïve T cell population (data not 
shown). 
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FIGURE 21. TCR Vß repertoire of MHC class I peptide-primed T cells after in vivo immunization. 
Bars represent mean (± SD) of duplicates from 2 animals per group. TCR Vß repertoire in Pc-
primed T cells was used as control. 
TCR Vß genes 
 
In comparison to the Pc-primed T cells, immunization with the immunogenic peptides 
P1-P4 activated characteristic TCR Vß subpopulations, which slightly differ from the 
control Pc (Figure 21). For example, P1-primed T cells overexpressed Vß 6, 8.1, 8.3, 
9, 11, 12, 16, 19 genes. These results indicate that immunization with such 
allopeptides modify the TCR repertoire of naïve T cells. 
 
4.15 TCR Vß repertoire of P1-primed T cells after in vitro restimulation 
The next question was whether repetitive in vitro restimulation gives rise to a 
restriction or alteration in the TCR Vß repertoire. The TCR Vß repertoire of Pc-primed 
FIGURE 22. TCR Vß repertoire after serial in vitro restimulation of P1-primed T cells. Arrows
indicate the overexpressed TCR Vß genes after 2-fold in vitro restimulation. Bars represent
mean (± SD) of duplicates from 2 animals per group. TCR Vß in Pc-primed T cells was used as
control.
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T cells was used as control. As described above (Figure 21), T cells isolated after 
immunization with peptide P1 have an oligoclonal TCR Vß repertoire (Vß 6, 8.1, 8.3, 
9, 11, 12, 16, 19), whereas after the second cycle of in vitro restimulation (14 days), 
the TCR Vß repertoire changed to Vß 4, 10, 14, 15, 17, 18, 19, 20 genes (Figure 22). 
These results show that repetitive in vitro restimulation induces a different TCR Vß 
repertoire in P1-primed T cells compared to those T cells that were freshly isolated 
after 7 days post-immunization. Therefore, further investigations are necessary to 
analyze the effect of the dominant peptide P1 in the induction and maintenance of the 
alloimmune response in vitro as well as in vivo. 
4.16 TCR Vß repertoire of graft-infiltrating lymphocytes after allotransplantation  
The next step was to investigate whether the same TCR subpopulations, 
characterized above after 2-fold in vitro restimulation, are involved in the rejection of 
FIGURE 23. Comparative presentation of TCR Vß repertoires in GILs harvested on day 5 (A) and 
at rejection time (B), from P1-immunized (P1 + HTx) and non-immunized (HTx) recipients. TCR 
Vß repertoire in Pc-primed T cells was used as control. Bars represent mean (± SD) of 
duplicates from 2 animals per group. Arrows indicate the overexpressed Vß in GILs from P1-
immunized (dashed) and non-immunized (black) recipients at the time of rejection. 
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WF allografts in LEW recipients. Therefore, graft-infiltrating lymphocytes (GILs) were 
harvested from P1-immunized LEW recipients on day 5, the day of complete 
rejection. GILs were analyzed from the non-immunized recipients on day 5 (non-
rejected grafts) and day 8, the day of complete rejection in these animals. As 
illustrated in Figure 23 (B), GILs isolated at the time of rejection from both P1-
immunized (day 5) and non-immunized (day 8) recipients are characterized by almost 
the same TCR Vß subpopulations Vß 6, 8.1, 8.3, 9, 12, 16, and 19, in comparison to 
Pc-primed T cells as control (Figure 23 (A)). The TCR Vß repertoire in GILs from 
rejected hearts in non-immunized recipients slightly differs from that identified on day 
5 (non-rejected grafts). Interestingly, the TCR Vß repertoire in the rejected grafts 
correlates with the profile observed after in vitro restimulation of P1-primed T cells 
P1, suggesting a particular role of these TCR Vß subpopulations in the activation of 
alloreactive T cells after immunization and/or transplantation. 
4.17 TCR Vß usage of P1-derived peptide analogue-primed T cells  
The analogues (A1.1-A1.6) derived from the immunodominant peptide P1 were 
analyzed to determine whether the substitutions of the allogeneic positions in P1 
influence the TCR Vß repertoire.  
TABLE 9. TCR Vß repertoire in peptide analogue-primed T cells in comparison to the control 
peptide Pc-primed T cells.  
Peptide analogue Overexpressed TCR Vß genes 
P1 Vß 6, 8.1, 8.3, 9, 11, 12, 16, 19 
A1.1 (L9 T10) Vß 2, 5.2, 6, 8.1, 8.3, 9, 12, 15, 16, 19 
A1.2 (L5 T10) Vß 2, 5.2, 6, 8.1, 8.3, 14, 15, 16, 19 
A1.3 (L9 T10) Vß 5.2, 6, 8.3, 9, 15, 16, 17, 19 
A1.4 (T10) Vß 5.2, 6, 8.1, 8.3, 9, 12, 15, 16, 17, 19 
A1.5 (L5) Vß 2, 4, 5.2, 6, 8.1, 8.3, 9, 14, 15, 16, 19 
A1.6 (L9) Vß 2, 4, 5.2, 6, 8.1, 8.3, 9, 14, 15, 16, 19 
 
As shown in Table 9, the overexpression of TCR Vß 6, 8.3, 16, and 19 genes 
obtained in P1-primed T cells was also found for all the P1-derived analogues (see 
Appendix). These results show that the substitutions in the allogeneic position are still 
able to activate some wt peptide P1-specific TCR subpopulations. In addition, each 
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analogue induces, after immunization, the activation of some other specific TCR Vß 
genes. 
The next question to address was whether the TCR subpopulations involved in the 
allograft rejection are also seen in the graft-infiltrating lymphocytes (GILs) isolated 
from the analogue-immunized recipient. As shown in Figure 24 (A), TCR Vß 6, 8.1, 
8.3, 9, 12, 16, 17 and 19 represented most of the Vß expressions in GILs of rejected 
grafts, when recipients were immunized with the agonist A1.1 (day 5) or analogue 
A1.5 (day 8) comparable to P1-immunized recipients. There were no differences 
between the TCR Vß usage of GILs isolated from A1.5-immunized animals on day 5 
(non-rejected grafts) and day 8 (rejected grafts) (Figure 24 (B)). Thus, one may 
conclude that the immunmodulatory ability of the MHC competitor A1.5 does not 
involve the activation of a specific TCR subpopulation.  
FIGURE 24. Comparative presentation of TCR Vß repertoires in GILs harvested on day 5 (A)
and at rejection time (B). TCR Vß repertoire in the Pc-primed T cells was used as control. Bars
represent mean (± SD) of duplicates from 2 animals per group. Arrows indicate the
overexpressed TCR Vß in GILs from A1.1 (dashed) and A1.5-immunized (black) recipients at
the time of rejection. 
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Summary 4.14 – 4.17: The four immunogenic allopeptides activate characteristic 
TCR Vß subpopulations after in vivo immunization. In addition, the overexpression of 
some TCR Vß subpopulations in the GILs, isolated from the rejected grafts of P1 or 
A1.5-immunized recipients, correlates with the profile observed after repetitive 
specific in vitro stimulation of P1-primed T cells. Our finding correlates with data from 
some groups that described a diverse TCR Vß usage (Kato et al. 1996), in contrast to 
others, which report a restricted one (Shirwan et al. 1993). In addition, we found no 
correlation between the modulation of the alloimmune response through analogues 
such as A1.5 and a specific TCR Vß subpopulation.  
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5. DISCUSSION 
The accessibility of sequence data for the mouse, rat, and human major 
histocompatibility complex (MHC) provides the opportunity to study the role of self-
restricted T cell allorecognition in allograft rejection using synthetic MHC-derived 
peptides. In this study, we present evidence that the MHC class I allopeptides are 
important for the indirect pathway of allorecognition involved in allograft rejection.  
5.1 The importance of donor MHC class I peptides in the induction of a T cell 
alloimmune response 
The indirect pathway of allorecognition is dependent on the ability of recipient APCs 
to process and to present the donor MHC peptides that can be recognized as 
immunogenic by recipient T cells. Our finding that the synthetic MHC class I 
allopeptides are recognized by the CD4+ T cells in the context of MHC class II 
molecules is consistent with the data from human and rodent experiments (Shirwan 
et al. 1995; Stegmann et al. 2000). We were able to demonstrate the central role 
attributed to CD4+ T cells by the resulting increase in the number of CD4+ CD25+ T 
cells in the regional lymph nodes after immunization with immunogenic peptide and 
secondly, by the lack of proliferation of peptide-primed T cells in the presence of anti-
MHC class II and anti-CD4 antibodies. In addition, it has been recently demonstrated 
that the majority of alloreactive CD4+ T cells recognize MHC-bound peptides, thus, 
underlying the dependency of the alloimmune response on peptides (Mendiratta et al. 
1999). 
5.1.1 Hierarchical distribution of the immunogenicity of MHC class I 
allopeptides 
An important feature of the indirect pathway is that the T cell response to an 
allopeptide may be limited to one or only a few dominant antigenic determinants, 
thus, focusing the T cell response to a selected number of allopeptides (Sercarz et al. 
1993). The dominant determinants from the donor MHC molecules are efficiently 
processed and presented, and afterwards activate the alloreactive T cells during 
allograft rejection. While it is difficult to predict which particular donor MHC-derived 
peptide induces an alloreactive T cell response, the aim of this study was to screen 
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the WF MHC class I molecule (RT1.Au) in order to ascertain the immunogenicity 
distribution within it. The seven synthetic RT1.Au peptides (P1-P7) that span the α1 
and α2 domains of the MHC class I molecule cover 29 of the 34 disparate amino 
acids (85% of the disparities). Five (P1-P5) of the 7 peptides tested were found to 
induce a specific T cell proliferation in LEW responders. In addition, it is a hierarchical 
distribution of the immunogenicity of allopeptides: peptide P1 is immunodominant, 
while P2, P3, P4, and P5 are the subdominant peptides, and P6 and P7 are the non-
immunogenic peptides (Sitaru 2002). The presence of such dominant allopeptides is 
comparable to other studies using a series of overlapping MHC peptides in other rat 
strain combinations (Lovegrove et al. 2001) and in mice (Benichou et al. 1994). 
Furthermore, the immunodominance of P1 was confirmed by the induction of a strong 
proliferation of those T cells that were primed after immunization with a mixture of five 
peptides and by the high levels of cytokines (IL-2, IFN-γ) produced upon in vitro 
restimulation.  
The hierarchical distribution of allopeptide immunogenicity within the RT1.Au 
molecule shows a direct correlation with their location. The highly immunogenic 
peptides (P1, P2, and P3) are located on the α1 domain, covering the β-pleated 
sheet region, whereas the non-immunogenic peptides are located on the α2 domain. 
In the WF-ACI strain combination, the dominant RT1.Au peptide is localized at the 
end of a α-helical region of the α2 domain (Chowdhury et al. 1998), while in the ACI-
WF combination, the location of the dominant RT1.Aa peptide corresponds to the α-
helical region of α1 domain. These data indicate the specificity of the 
immunodominant peptide for a certain donor-recipient MHC combination, but the 
location is indisputable within the hypervariable regions of donor MHC class I 
molecules.  
In addition, it is well known that the MHC disparities between donor and recipient are 
responsible for the induction of the alloimmune response. Surprisingly, the 
immunogenicity appeared to be unconstrained by the number of differences between 
donor and recipient amino acid sequences. The peptides P4 and P6, in which 7 (of 
22) and, respectively, 8 (of 24) amino acids are different, were the least immunogenic 
of the 7 peptides, as demonstrated by in vitro proliferation and cytokine production. In 
contrast, the high immunogenic allopeptides P1, P2, and P3 consist of only 3 
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allogeneic amino acids each. Therefore, the number of donor-recipient differences 
appears to play a negligible role in immunogenicity, although the type of these amino 
acids (the structure and the special characteristics of each amino acid) may be of 
great significance for the subsequent T cell recognition and activation.  
5.1.2 Influences of MHC class I allopeptides on the allograft survival time 
Since there is increasing evidence indicating the importance of allopeptides in 
mediating graft rejection, the immunogenicity of such peptides was further tested in a 
heterotopic heart transplantation model. Our finding that LEW (RT1.Al) recipients 
immunized with immunogenic RT1.Au allopeptides (P1, P3, respectively) 9 after the 
transfer of P1-primed T cells reject their allografts more rapidly compared to non-
immunized animals is supported by studies in rodent transplantation models 
(Fangmann et al. 1992; van Denderen et al. 2001). Interestingly, immunization with 
the subdominant peptide P3 resulted in an accelerated heart graft rejection 
comparable to the dominant peptide P1 (see Figure 12); it is possible to suppose that 
in the allograft situation the subdominant determinants are also sufficient to activate 
the T cell alloimmune response and subsequently, to initiate the allograft rejection. In 
order to explain this observation, further investigations are required. 
5.1.3 Influence of dominant allopeptide on the TCR Vß repertoire of alloreactive 
T cells 
It has been shown that immunodominance leads to limitations in the TCR repertoire 
of alloreactive CD4+ T cells (reviewed by Douillard et al. 1999). Fasso demonstrated 
the early selection of TCR repertoire resulting in a relatively homogenous T cell 
population, a phenomenon known as clonal selection in the CD4+ compartment 
(Fasso et al. 2000). Different groups have studied the TCR Vß usage of T cells 
activated during in vivo and in vitro alloresponses in both animal models (Douillard et 
al. 1998; Guillet et al. 2002) and humans (Datema et al. 1994). We found almost the 
same TCR Vß profile after serial in vitro restimulation of P1-primed T cells and in 
freshly isolated GILs from rejected hearts. Since our in vitro conditions allow the 
indirect pathway of recognition to occur, the data demonstrate the implication of this 
pathway in the induction of acute rejection.  
In summary, the WF MHC class I (RT1.Au) peptide P1 is immunodominant due to the 
activation of recipient’s alloimmune system, as confirmed by in vitro proliferation and 
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cytokine production of P1-primed T cells as well as by the reduction of allograft 
survival time in P1-immunized and/or P1-primed T cells transferred to LEW recipients 
(RT1l).  
5.2 Peptide analogues from the dominant allopeptide as a strategy to modulate 
the alloimmune response 
As a step toward developing more efficient tools for antigen-specific suppression of 
the alloimmune response, it has been demonstrated that the activation of the 
alloreactive T cells induced by the dominant allopeptide can be altered by fine 
changes in the amino acid sequence. Data are available concerning the modulation 
of the T cell alloimmune response as a strategy to develop antigen-specific therapy, 
through the use of altered peptide ligands (APLs) or peptide analogues of an 
immunodominant antigen. Therapeutic APLs have been studied in more detail in 
experimental autoimmune diseases such as multiple sclerosis, and rheumatoid 
arthritis (Anderton 2001), and type 1 diabetes (Alleva et al. 2002), in which APLs are 
derived from the dominant epitopes of the autoantigens. These APLs were able to 
competitively inhibit the activation of native peptide-specific T cell clones. Based on 
the experimental data of EAE, there were initiated phase II clinical trials for the 
treatment of multiple sclerosis in humans (Bielekova et al. 2000). 
In the previous set of experiments we have demonstrated that RT1.Au peptide P1 
with three allogeneic positions (5, 9, and 10) is dominant in LEW (RT1.Al) recipients. 
The next step was to design and characterize “recipient-adapted” analogues from P1. 
The analogues (A1.1-A1.6) were generated from P1 by changing the allogeneic 
RT1.Au amino acids (L5, L9, and T10) one by one with the corresponding syngeneic 
RT1.Al amino acids (M5, D9, and I10). Our results demonstrate that the analogues, 
consisting of either one or two allogeneic amino acids are still able to induce a 
specific T cell proliferative response. The proliferative capacity did not correlate well 
with the specific cytokine productions. For example, analogue A1.5 with only one 
allogeneic amino acid (L5) had a weaker specific proliferative capacity associated 
with higher levels of cytokines (IL-2, IFN-γ, IL-4, and IL-10) as compared to the wild-
type peptide P1. By taking advantage of the in vivo model of transplantation, we have 
shown that the agonist A1.1 is able to strongly activate the rejection mechanisms 
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(like P1), while A1.5 seems to have only minimal influence (no reduction in allograft 
survival time).  
We hypothesized that such substitutions in the dominant peptide are able to induce 
the activation of other TCR Vß subpopulations in comparison to the wild-type peptide. 
The TCR Vß repertoire analysis of T cells activated after immunization with the 
individual peptide analogues indicated the presence of several common TCR 
subpopulations (TCR Vß 6, 8.1, 8.3, 9, 16, and 19). Therefore, our initial hypothesis 
was not really sustained and the data indicate that such analogues maintain the 
ability to activate the wild-type peptide-specific TCR subpopulations. 
Since the analogues show various T cell activation capacities, we then analyzed the 
specificity of the T cells activated after immunization with the wild-type peptide P1 for 
its analogues. Afterwards, the analogues were classified as follows: A1.1 and A1.6 as 
agonists (the same proliferation) and A1.2, A1.3, and A1.4 as weak agonist peptides 
(weaker proliferation). In contrast, analogue A1.5 was able to down-regulate the 
proliferation of P1-primed T cells.  
The mechanisms responsible for this effect are still subject to investigation (Kersh et 
al. 1996). Therefore, we postulated that it is possible to induce a lasting negative 
signal through the TCR (anergy) or that it acts as a competitor for the MHC-binding 
site respectively. Since A1.5 did not influence the proliferation of P1-primed T cells 
when cells were pre-incubated with A1.5-pulsed DCs and then rechallenged with the 
P1-pulsed DCs, we conclude that it is unlikely that A1.5 induced a permanent 
negative signal through the TCR of P1-primed T cells. However, in an elegant study, 
using T cell clones from transplanted patients, it has been demonstrated that partial 
agonists could be used to induce unresponsiveness to the dominant MHC class I 
allopeptide (Frasca et al. 2000).  
These results strongly support the idea that the down-regulation of the proliferation in 
P1-primed T cells depends on an early event of T cell activation, such as MHC 
presentation, rather than the induction of a general state of anergy or 
unresponsiveness. Thus, in a MHC competition assay, A1.5 appears to display 
higher MHC binding affinity than the wild-type peptide P1, inhibiting P1-primed T cell 
proliferation when presented on the same DCs, in equimolar amount.  
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Consistent with this in vitro ability of A1.5, we found an in vivo suppression of the 
early induction of allograft rejection when recipients were immunized with a mixture of 
A1.5 and P1 (allograft rejection as in non-immunized recipients). This effect could be 
explained by the competition for binding to the MHC molecule, which thus allows 
A1.5 to control the induction of allograft rejection. Similar observations have been 
previously reported for the experimental allergic encephalomyelitis (EAE) in a mouse 
model (Kumar et al. 1990). In this study, a doubly substituted analogue from the 
myelin basic protein (MBP) was described, which binds with high affinity to the MHC 
molecule and seems to be protective against EAE as well as effective in reversing 
established EAE. 
In addition, our recent results indicated that recipients immunized separately in one 
footpad with one of the peptides P1 or A1.5 rejected their allograft similar to those 
immunized in both footpads with P1. In this situation, P1 had no competition for MHC 
binding and, therefore, induced an early graft rejection. Moreover, it has been 
suggested that the interaction with such altered peptide ligands can result in different 
phenotypes of the T cells, from selective stimulatory functions to a complete switch 
(immune deviation) in their function (Sloan-Lancaster et al. 1996). In order to 
acknowledge this, further investigations of the T cell functions after a rechallenge with 
analogues are required.  
To summarize, our data show the possibility of investigating the fine specificity of 
dominant peptide P1 using peptide analogues. Our results indicate that the 
immunogenicity is dependent on the presence of the allogeneic position and 
furthermore, that there is no linear relationship between the number of the allogeneic 
positions and the immunogenic ability. Analogue A1.5, with only one allogeneic 
amino acid (L5) was found to be a good candidate for analyzing the modulation of 
P1-induced alloimmune response, because it induced the lowest proliferation 
associated with high cytokine production (IL-4 and IL-10) and, in addition, did not 
influence the allograft survival time. We demonstrated that A1.5 acts as a MHC 
competitor in vitro as well as in vivo and feel that further investigations are necessary 
to clarify the responsible mechanisms.  
These observations emphasize the possibility that analogues or APLs from the 
dominant allopeptide represent a promising antigen-specific strategy to suppress the 
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alloimmune response responsible for the potential graft damages. Further studies 
should investigate the ability of such analogues not only to prevent the early 
activation of rejection mechanisms, but also to suppress the alloimmune response 
after transplantation resulting in a prolongation of the allograft survival time. 
In conclusion, the immunosuppressive drugs will probably remain the backbone 
support system to suppress the alloimmune response, in combination with a more 
selective and specific therapy with minimal toxic side effects, such as the altered 
peptide ligands. 
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SUMMARY 
Transplantation is now firmly established as a therapeutic approach to extend and 
improve the life of patients in the final stages of organ failure. It has been 
demonstrated that transplantation between genetically non-identical individuals leads 
to the activation of the recipient’s alloimmune response as a major determinant of 
transplant outcome. T cell recognition of foreign MHC molecules plays a key role in 
initiating and sustaining allograft rejection. To prevent the risk of rejection, patients 
are given immunosuppressive drugs, which are non-specific and have major side-
effects (infections, malignancies). It has been shown that the alloreactive T cells 
specifically recognize donor MHC-derived peptides. This implies that it may be 
possible to develop antigen-specific strategies in order to modulate the alloimmune 
response by peptide analogues and specifically altered peptide ligands. 
The purpose of this study was to explore the potential of “recipient-adapted” 
analogues from the dominant MHC class I peptide to modulate the alloimmune 
response. Beside the significant role of donor dominant determinants in the rejection 
process, we tested seven 13-to-24-mer peptides from the Wistar-Furth MHC class I 
molecule (WF, RT1.Au) for their possible immunogenicity in a fully MHC-mismatched 
WF to Lewis (LEW, RT1l) rat strain combination. Secondly, the immunodominant 
allopeptide was selected to generate analogues in order to investigate their 
modulatory capacity. All peptides were tested in vitro in a standard proliferation assay 
and in vivo using a heterotopic heart transplantation model. 
Our findings show that five peptides (P1-P5) were able to induce specific T cell 
proliferation in LEW responders. Furthermore, we found a hierarchical distribution of 
the determinants: peptide P1 as a good candidate for the immunodominant 
determinant, while P2, P3, P4, and P5 as subdominant epitopes and the other two 
peptides, P6 and P7, as non-immunogenic determinants of WF MHC class I 
molecule. Furthermore, the dominance of P1 was confirmed by the strong 
proliferation induced after immunization with a mixture of peptides in the presence of 
P1. This hierarchical distribution of the proliferative response correlated with the 
cytokine production. Peptide P1, comprising only 3 allogeneic amino acids (L5, L9, 
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and T10) induced the strongest T cell proliferation and produced high levels of 
cytokines, especially IL-2 and IFN-γ. In addition, the immunodominance of peptide P1 
was confirmed by the significant reduction in the allograft survival time in comparison 
to the non-immunized control animals. Since the TCR Vß repertoire of rejected graft-
infiltrating cells in rejected allografts was similar to the profile observed after in vitro 
restimulation of P1-primed T cells, we concluded that peptide P1 is able to activate 
the alloreactive T cell population. Our results demonstrate the particular role of the 
dominant peptide P1 (residues 1-19) in the allograft rejection in WF to LEW rat strain 
combination.  
In the second set of experiments, we investigated the fine specificity of the dominant 
peptide P1-activated T cells using peptide analogues from P1. The “recipient-
adapted” analogues were designed by changing the allogeneic RT1.Au amino acids 
(L5, L9, T10) one-by-one with the correspondent syngeneic RT1.Al amino acids (M5, 
D9, I10) in the sequence of peptide P1. The six peptide analogues (A1.1-A1.6) 
consisting of either one or two allogeneic amino acids were able to induce a specific 
T cell proliferative response and cytokine production. Analogue A1.5 with only one 
allogeneic amino acid (L5) was of particular interest because it induced a low T cell 
proliferation and high cytokine levels, especially IL-4 and IL-10. In addition, 
immunization with A1.5 did not influence the allograft survival time in comparison to 
the non-immunized LEW recipients. A1.5 was the only analogue able to down-
regulate the proliferation of P1-primed T cells. Our results reveal that A1.5 is an MHC 
competitor as confirmed by the in vitro MHC competition assay and the inhibition of 
the negative effect of P1 on the allograft survival time when recipients were 
immunized with a mixture of P1 and A1.5.  
These findings suggest that it is possible to design peptide analogues, such as A1.5, 
which do not stimulate the dominant peptide P1-specific T cell population and even 
more, are able to block its presentation in the MHC molecule. 
In all, the results indicate that the specific suppression of indirect allorecognition can 
be achieved by using peptide analogues of the dominant allopeptide. 
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ZUSAMMENFASSUNG 
Ursache der Transplantatabstoßung ist in erster Linie die genetische Differenz im 
Haupthistokompatibilitätskomplex (MHC) zwischen Transplantatspender und 
Empfänger. Dabei stellen die aus den Fremd-MHC-Molekülen durch empfänger-
eigene antigenpräsentierende Zellen prozessierten MHC-Peptide einen wichtigen 
Stimulus zur Aktivierung alloreaktiver T-Lymphozyten des Transplantat empfängers 
dar. Für die Transplantation bedeutsam ist, dass sowohl diese, als auch synthetische 
MHC-Peptide, wenn sie die genetische Differenz zwischen einer bestimmten 
Spender-Empfänger-Kombination repräsentieren, die Alloimmunantwort induzieren 
und damit die Abstoßung fördern.  
Das Ziel dieser Arbeit war, dass bereits in zahlreichen Experimentalmodellen für 
Autoimmunerkrankungen erfolgreiche Konzept der antigenspezifischen 
Immuntherapie mit Peptidvarianten oder altered peptide ligands auf die 
Transplantation zu übertragen. Anders als bei Autoimmunerkrankungen basiert die 
Alloimmunantwort aber nicht auf ein einyelnes Peptidantigen und darüber hinaus 
beeinflußt die jeweilige Spender-Empfänger-Kombination sehr stark dieses 
Peptidantigen-Repertoire.  
Um die Frage zu klären, welche der potentiellen MHC-Peptidantigene in der 
Alloimmunaktivierung dominieren, wurden Untersuchungen im Nagermodell für die 
allogene Spender-Empfänger-Kombination Wistar-Furth (WF, RT1u) und Lewis 
(LEW, RT1l) durchgeführt. Für die Transplantation wird erwartet, dass solche gezielt 
hergestellten Peptidvarianten sowohl die Aktivierung alloreaktiver T-Lymphozyten als 
auch weitere Funktionen, wie z. B. die Produktion von Cytokinen, hemmen. Dieser 
antigenspezifische, und wahrscheinlich auch nebenwirkungsfreie Therapieansatz 
könnte möglicherweise zur langfristigen Erhaltung der Transplantatfunktion führen. 
Durch Vergleich der Sequenzen für das MHC-Klasse-I Molekül beider Ratten-
Stämme wurden für die α1 und α2 Domäne - dies ist der extrazelluläre, für die 
Bindung von Peptiden unterschiedlichster Herkunft verantwortliche Bereich des 
Moleküls - insgesamt 34 Positionen identifiziert, in denen beide Stämme 
unterschiedliche Aminosäuren aufweisen. Diese Differenzen werden von sieben 
synthetischen, mit den entsprechenden Bereichen des Spender MHC-Klasse-I 
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Moleküls identischen MHC-Peptiden repräsentiert, welche zwischen 13 und 24 
Aminosäuren lang sind.  
Die immunstimulierende Wirkung dieser Peptide (P1 bis P7) wurde im 
Proliferationsassay und im Transplantationsmodell bestimmt. Ausschließlich das 
Peptid mit der Bezeichnung P1 induzierte mit über 20.000 cpm die stärkste, mit einen 
Th1-dominierten Cytokinmuster (IL-2 und IFN-γ) einhergehende T-Zellproliferation. 
Lewis-Empfänger, die vor der Transplantation mit diesem Peptid immunisiert wurden, 
stießen ihre von WF-Spendern stammenden heterotopen Herztransplantate 
beschleunigt ab. Von sieben potentiellen Peptidantigenen induzierte somit 
ausschließlich Peptid P1 eine dominante Alloimmunaktivierung und erscheint als 
Peptidantigen zur Herstellung von Peptidvarianten prädestiniert.  
P1 weicht in drei Aminosäurepositionen von der entsprechenden Sequenz der Lewis-
Ratte ab. Durch sequentiellen Austausch dieser drei in der WF-Sequenz befindlichen 
allogenen Aminosäuren durch die entsprechenden syngenen Aminosäuren in der 
LEW-Sequenz führte zu sechs Peptidvarianten. Diese Empfänger-angepassten 
Varianten A1.1 bis A1.6 wurden anschließend auf ihre Fähigkeit untersucht, eine 
peptidspezifische T-Zellproliferation zu inhibieren, die möglicherweise mit einer 
protektiven Wirkung auf die Transplantatfunktion einhergeht. Von diesen 
Peptidvarianten induzierte nur Variante A1.5, sie besitzt noch eine allogene 
Aminosäure an Position 5, eine reduzierte T-Zellproliferation von 11.450 cpm, die mit 
einem Th2-dominierten Cytokinmuster (IL-4 und IL-10) korreliert. Zusätzlich hemmte 
A1.5 die Proliferation der P1-spezifischen T-Lymphozyten. Im Gegensatz zum 
Ausgangs-peptid P1 beeinflußte A1.5 nicht die Abstoßung heterotoper 
Herztransplantate und konnte, wurde es in Kombination mit P1 appliziert, die P1-
induzierte Transplantatabstoßung verzögern.  
Um diese immunmodulatorische Fähigkeit der Variante A1.5 weiter zu untersuchen, 
wurde das Peptid in einem T-Zellrezeptor-Modulationsassay sowie in einem MHC-
Kompetitionsassay getestet. Die Ergebnisse zeigten, dass A1.5 nicht die T-
Zellproliferation über den T-Zellrezeptor inhibiert, sondern über die verstärkte 
Bindung an das MHC-Klasse-II Molekül, wodurch das Peptid P1 wahrscheinlich aus 
der Bindungstasche verdrängt wird. Dieses Ergebnis wurde von weiteren in vivo 
Daten unterstützt. Wurden beide Peptide getrennt und nicht im Gemisch appliziert, 
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konnte A1.5 die abstoßungsinduzierende Wirkung von P1 nicht mehr kompensieren, 
und das Transplantat wurde zum gleichen Zeitpunkt nach Transplantation 
abgestoßen wie in P1-immunisierten Tieren.  
Die Peptidvariante A1.5 wirkt somit als MHC-Kompetitor und verhindert die P1-
induzierte Aktivierung alloreaktiver T-Lymphozyten. Die Ergebnisse zeigen, dass die 
gezielte Herstellung von Varianten aus dem immundominanten MHC-Klasse-I Peptid 
für eine bestimmte Spender-Empfänger-Kombination somit eine mögliche 
Perspektive zur antigenspezifischen Hemmung der Transplantatabstoßung darstellt. 
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APPENDIX 
TCR Vß repertoire of T cells primed after in vivo immunization with “recipient-
adapted” peptide analogues (A1.1-A1.6), in comparison to Pc-primed T cells as 
control. 
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